Matrix metalloproteinases and angiogenic factors: Predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?

American Journal of Pathology

Volumn 177, Issue 5, 2010, Pages 2216-2224

  Boxler, Silvan ^a,b   Djonov, Valentin ^a   Kessler, Thomas M ^b   Hlushchuk, Ruslan ^a   Bachmann, Lucas M ^c   Held, Ulrike ^c   Markwalder, Regula ^b   Thalmann, George N ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CD31 ANTIGEN; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 19; STROMELYSIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CORRELATION ANALYSIS; DISEASE SPECIFIC SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TISSUE MICROARRAY;

EID: 78149349200     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091190     Document Type: Article

References (63)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistics, 2008. CA: a Cancer Journal for Clinicians 2008, 58:71-96
2. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F: EAU guidelines on prostate cancer. Eur Urol 2005, 48:546-551
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364
4. Fingleton B: Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006, 11:479-491
5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, Investigators E: Screening and prostate-cancer mortality in a randomized European study.[see comment]. N Engl J Med 2009, 360:1320-1328
6. Roy R, Yang J, Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297
7. Kessler TM, Burkhard FC, Studer UE: Nerve-sparing open radical retropubic prostatectomy. Eur Urol 2007, 51:90-97
8. Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG, Studer UE, Thalmann GN: Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 2005, 174:1814-1818, discussion 1818
9. Longfordt NT: Single imputation and related methods. Edited by Longfordt NT. London, Springer 2005, pp. 37-58
10. Hsieh FY, Lavori PW: Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000, 21:552-560
11. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD: Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and metaanalysis. Lancet Oncology 2007, 8:411-419
12. Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC, Carroll PR: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001, 165:851-856
13. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:110-114 (Pubitemid 23175983)
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374
15. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451
16. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994, 152:1837-1842
17. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994, 152:1850-1857
18. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994, 152:1831-1836
19. Sauer CG, Kappeler A, Spath M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R: Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 2004, 444:518-526
20. Festuccia C, Bologna M, Vicentini C, Tacconelli A, Miano R, Violini S, Mackay AR: Increased matrix metalloproteinase-9 secretion in shortterm tissue cultures of prostatic tumor cells. Int J Cancer 1996, 69:386-393
21. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2. MMP-9) markers of prostate cancer. Urol Res 2005, 33:44-50
22. Zhang S, Li L, Lin JY, Lin H: Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003, 9:899-904
23. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744
24. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR: A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003, 10:823-832
25. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621-7628
26. Vasala K, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Research 2008, 28:1757-1761
27. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005, 9:267-285
28. Hamano Y, Kalluri R: Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 2005, 333:292-298
29. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998, 161:6845-6852
30. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M: Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clinical Cancer Res 2008, 14:7470-7480
31. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW: Osteopontin: possible role in prostate cancer progression. Clinical Cancer Res 1999, 5:2271-2277
32. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC: Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000, 42:18-25
33. Stearns ME, Stearns M: Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. Oncol Res 1996, 8:63-67
34. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA: Relative expression of type IV collagenase. E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000, 6:2295-2308
35. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Jr., Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003, 16:198-205
36. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997, 15:246-258
37. Sternlicht MD, Bissell MJ, Werb Z: The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000, 19:1102-1113
38. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146
39. McCawley LJ, Crawford HC, King LE, Jr., Mudgett J, Matrisian LM: A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004, 64:6965-6972
40. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research 2003, 92:827-839
41. Djonov V, Hogger K, Sedlacek R, Laissue J, Draeger A: MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. J Pathol 2001, 195:147-155
42. Velinov N, Aebersold D, Haeni N, Hlushchuk R, Weinstein F, Sedlacek R, Djonov V: Matrix metalloproteinase-19 is a predictive marker for tumor invasiveness in patients with oropharyngeal squamous cell carcinoma. Int J Biol Markers 2007, 22:265-273
43. Hashimoto K, Kihira Y, Matuo Y, Usui T: Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998, 160:1872-1876
44. Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ: Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis 2003, 6:15-26
45. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835
46. Zhong H, Semenza GL, Simons JW, De Marzo AM: Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004, 28:88-93
47. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA: Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 2009, 69:4708-4715
48. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000, 45:72-79
49. Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh-Xuan AT: The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int 2007, 99:1150-1153
50. Mao K, Badoual C, Camparo P, Delongchamps NB, Vieillefond A, Dinh-Xuan AT, Peyromaure M: The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy. Canadian J Urol 2008, 15:4257-4262
51. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M: Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003, 43:309-319
52. Trojan L, Thomas D, Knoll T, Grobholz R, Alken P, Michel MS: Expression of pro-angiogenic growth factors VEGF, EGF, and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res 2004, 32:97-103
53. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA: Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 2006, 448:68-74
54. Strohmeyer D, Strauss F, Rossing C, Roberts C, Kaufmann O, Bartsch G, Effert P: Expression of bFGF. VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 2004, 24:1797-1804
55. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002, 94:883-893
56. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA: Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res 2000, 20:3791-3799
57. Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S: Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000, 42:26-33
58. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R: Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002, 5:123-127
59. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994, 73:678-687
60. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143:401-409
61. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005, 97:1248-1253
62. Bubendorf L, Nocito A, Moch H, Sauter G: Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001, 195:72-79
63. Rubin MA, Dunn R, Strawderman M, Pienta KJ: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002, 26:312-319